BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24794217)

  • 1. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
    Shibuya KC; Goel VK; Xiong W; Sham JG; Pollack SM; Leahy AM; Whiting SH; Yeh MM; Yee C; Riddell SR; Pillarisetty VG
    PLoS One; 2014; 9(5):e96565. PubMed ID: 24794217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
    Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
    Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
    Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
    Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.
    Tang Y; Xu X; Guo S; Zhang C; Tang Y; Tian Y; Ni B; Lu B; Wang H
    PLoS One; 2014; 9(3):e91551. PubMed ID: 24637664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.
    Bayne LJ; Beatty GL; Jhala N; Clark CE; Rhim AD; Stanger BZ; Vonderheide RH
    Cancer Cell; 2012 Jun; 21(6):822-35. PubMed ID: 22698406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
    Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy.
    Liu L; Zhao G; Wu W; Rong Y; Jin D; Wang D; Lou W; Qin X
    Cancer Immunol Immunother; 2016 Jan; 65(1):73-82. PubMed ID: 26646849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.
    Elahi-Gedwillo KY; Carlson M; Zettervall J; Provenzano PP
    Cancer Res; 2019 Jan; 79(2):372-386. PubMed ID: 30401713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
    Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
    J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
    Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
    Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.
    Mirlekar B; Michaud D; Searcy R; Greene K; Pylayeva-Gupta Y
    Cancer Immunol Res; 2018 Sep; 6(9):1014-1024. PubMed ID: 29980536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8
    Tada Y; Togashi Y; Kotani D; Kuwata T; Sato E; Kawazoe A; Doi T; Wada H; Nishikawa H; Shitara K
    J Immunother Cancer; 2018 Oct; 6(1):106. PubMed ID: 30314524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.
    Van YH; Lee WH; Ortiz S; Lee MH; Qin HJ; Liu CP
    Diabetes; 2009 Jan; 58(1):146-55. PubMed ID: 18984738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of a Type 2-Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
    Slauenwhite D; McAlpine SM; Hanly JG; Malik A; Haidl ID; Marshall JS; Issekutz TB
    Arthritis Rheumatol; 2020 Jul; 72(7):1091-1102. PubMed ID: 32039570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.